Projekt

Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) ½ inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: A randomized placebo-controlled double-blind phase II trial

Abgeschlossen · 2010 bis 2012

Hasler-Strub Ursula, Ruhstaller Thomas, Huober Jens, Mark Michael